Glycaemic control in patients with type 2 diabetes and colorectal- or breast cancer treated with curative intent
- Conditions
- Type 2 diabetes (T2DM)Breast cancer/borstkankerColorectal cancer/colorectale kankerHypertension/hypertensieDyslipidemia/dyslipidemie
- Registration Number
- NL-OMON23282
- Lead Sponsor
- Diabetes Kenniscentrum Zwolle
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 156
Patients with type 2 diabetes treated in primary care, who are diagnosed with primary breast- or colorectal cancer, between 1999 and 2012 and who are treated with curative intent. Curative intent for breast cancer was defined as stage 1 to 3 breast cancer or ductal carcinoma in situ (DCIS) of the breast. Curative intent for colorectal cancer was defined as stage 1 to 3, who received at least surgical treatment.
Patients with evidence of relapse, patients with other cancers than breast or colorectal cancer, or patients with a history of other cancers prior to breast or colorectal cancer with the exception for non-melanoma skin cancer and patients who received no cancer treatment or only hormone treatment in breast cancer are excluded. Patients without at least 1 year of follow-up in the ZODIAC study prior to the diagnosis of breast or colorectal cancer are also excluded.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The proportion of patients who achieve their individual treatment goal at 0, 12 months and 24 months after cancer diagnosis and treatment compared to baseline.
- Secondary Outcome Measures
Name Time Method The proportion of patients who achieve a target cholesterol/HDL ratio equal or below 4 at 0, 12 and 24 months compared to baseline. <br /><br>The proportion of patients who achieve a target systolic blood pressure equal to or below of 140 mmHg at 0, 12 and 24 months compared to baseline.